Patient and disease characteristics
| Characteristics . | Total . | CR, n = 16 (%) . | PD, n = 10 (%) . | P value∗ . |
|---|---|---|---|---|
| Age (y) at infusion | 55 ± 11 | 55 ± 9 | 54 ± 14 | .81 |
| Gender | ||||
| Female | 9 | 5 (31.25) | 4 (40.00) | .69 |
| Male | 21 | 11 (68.75) | 10 (60.00) | |
| Race/ethnicity | NA | |||
| Caucasian | 26 | 16 (100.00) | 10 (100.00) | |
| ECOG PS at baseline, n (%) | ||||
| 0 | 13 | 9 (56.25) | 4 (40.00) | .40 |
| 1 | 12 | 7 (43.75) | 5 (50.00) | |
| 2 | 1 | 0 (0) | 1 (10.00) | |
| Disease type, n (%) | ||||
| DLBCL | 16 | 9 (56.25) | 7 (70.00) | .54 |
| HGBCL | 3 | 1 (6.25) | 2 (20.00) | |
| PMBCL | 2 | 1 (6.25) | 1 (10.00) | |
| Richter transformation | 1 | 1 (6.25) | 0 (0.00) | |
| MCL | 1 | 1 (6.25) | 0 (0.00) | |
| FL | 3 | 3 (18.75) | 0 (0.00) | |
| Infusion product, n (%) | ||||
| Yescarta | 25 | 15 (93.75) | 10 (100.00) | 1 |
| Tecartus | 1 | 1 (6.25) | 0 (0) | |
| Primary refractory, n (%) | ||||
| No | 15 | 11 (73.33) | 4 (40.00) | .12 |
| Yes | 10 | 4(26.67) | 6 (60.00) | |
| MYC+FISH, n (%) | ||||
| No | 19 | 13 (86.67) | 6 (60.00) | .18 |
| Yes | 6 | 2 (13.33) | 4 (40.00) | |
| Double-hit FISH, n (%) | ||||
| No | 20 | 14 (93.33) | 6 (60.00) | .07 |
| Yes | 5 | 1 (6.67) | 4 (40.00) | |
| IPI at infusion (median) | 2 | 2 | 2 | 1 |
| IPI at infusion of ≥3, n (%) | ||||
| No | 19 | 13 (81.25) | 6 (60.00) | .37 |
| Yes | 7 | 3 (18.75) | 4 (40.00) | |
| Ann Arbor stage, n (%) | ||||
| I/II | 8 | 7 (33.75) | 1 (10.00) | .20 |
| III/IV | 18 | 9 (56.25) | 9 (90.00) | |
| Second-line or third-line or more CAR-T therapy, n (%) | ||||
| Second-line | 3 | 1 (6.25) | 2 (20.00) | .54 |
| Third-line or more | 23 | 15 (93.75) | 8 (80.00) | |
| Bridging therapy chemotherapy, n (%) | ||||
| No | 13 | 8 (50.00) | 5 (50.00) | 1 |
| Yes | 13 | 8 (50.00) | 5 (50.00) | |
| Bridging therapy, n (%) | ||||
| RT only | 1 | 0 (0) | 1 (16.67) | .43 |
| Systemic only | 13 | 8 (100.00) | 5 (83.33) | |
| Dexamethasone prophylaxis, n (%) | ||||
| No | 12 | 7 (43.75) | 5 (50.00) | 1 |
| Yes | 14 | 9 (56.25) | 5 (50.00) | |
| Characteristics | ||||
| Largest tumor diameter | ||||
| Mean, cm (range) | 5.77 (1.0-20.0) | 4.13 (1.1-10.0) | 8.41 (1.0-20.0) | .05 |
| Bulky, >5 cm, n (%) | ||||
| Yes | 10 | 4 (25.00) | 6 (60.00) | .11 |
| No | 16 | 12 (75.00) | 4 (40.00) | |
| Bulky, >7 cm, n (%) | ||||
| Yes | 7 | 2 (12.50) | 5 (50.00) | .07 |
| No | 19 | 14 (87.5) | 5 (50.00) | |
| Bulky, >10 cm, n (%) | ||||
| Yes | 6 | 2 (12.5) | 4 (40.00) | .16 |
| No | 20 | 14 (87.5) | 6 (60.00) | |
| SUVmax(mean ± SD) | 18.65 ± 10.94 | 14.97 ± 8.34 | 23.90 ± 12.64 | .10 |
| Disease response on preinfusion imaging, n (%) | ||||
| PD | 13 | 9 (56.25) | 4 (40.00) | .83 |
| Partial response | 8 | 4 (25.00) | 4 (40.00) | |
| Stable disease | 1 | 1 (6.25) | 0 (0.00) | |
| Stable disease/mixed | 2 | 1 (6.25) | 1 (10.00) | |
| N/A | 2 | 1 (6.25) | 1 (10.00) | |
| Circulating disease prior, n (%) | ||||
| Yes | 3 | 2 (13.33) | 1 (11.11) | 1 |
| No | 21 | 13 (86.67) | 8 (88.89) | |
| Extranodal disease, number of sites, n (%) | ||||
| 0 | 11 | 8 (50.00) | 3 (30.00) | .64 |
| 1 | 11 | 6 (37.50) | 5 (50.00) | |
| 2 | 3 | 2 (12.50) | 1 (10.00) | |
| 3 | 1 | 0 (0.00) | 1 (10.00) | |
| LDH at cell infusion, (mean ± STD), U/L | 288 ± 487 | 189 ± 32 | 445 ± 78 | .20 |
| LDH >190 U/L (ULN), n (%) | ||||
| No | 11 | 7 (43.75) | 4 (40.00) | 1 |
| Yes | 15 | 9 (56.25) | 6 (60.00) | |
| Ferritin at cell infusion, (mean ± SD), ng/mL | 456 ± 394 | 314 ± 202 | 684 ± 519 | .02 |
| Ferritin of >WNL, n (%) | ||||
| No | 16 | 13 (81.25) | 3 (30.00) | .02 |
| Yes | 10 | 3 (18.75) | 7 (70.00) | |
| CRP at cell infusion, (mean ± SD), mg/L | 30 ± 44 | 19 ± 27 | 48 ± 60 | .10 |
| CRP of >WNL, n (%) | ||||
| Yes | 10 | 3 (18.75) | 7 (70.00) | .02 |
| No | 16 | 13 (81.25) | 3 (30.00) |
| Characteristics . | Total . | CR, n = 16 (%) . | PD, n = 10 (%) . | P value∗ . |
|---|---|---|---|---|
| Age (y) at infusion | 55 ± 11 | 55 ± 9 | 54 ± 14 | .81 |
| Gender | ||||
| Female | 9 | 5 (31.25) | 4 (40.00) | .69 |
| Male | 21 | 11 (68.75) | 10 (60.00) | |
| Race/ethnicity | NA | |||
| Caucasian | 26 | 16 (100.00) | 10 (100.00) | |
| ECOG PS at baseline, n (%) | ||||
| 0 | 13 | 9 (56.25) | 4 (40.00) | .40 |
| 1 | 12 | 7 (43.75) | 5 (50.00) | |
| 2 | 1 | 0 (0) | 1 (10.00) | |
| Disease type, n (%) | ||||
| DLBCL | 16 | 9 (56.25) | 7 (70.00) | .54 |
| HGBCL | 3 | 1 (6.25) | 2 (20.00) | |
| PMBCL | 2 | 1 (6.25) | 1 (10.00) | |
| Richter transformation | 1 | 1 (6.25) | 0 (0.00) | |
| MCL | 1 | 1 (6.25) | 0 (0.00) | |
| FL | 3 | 3 (18.75) | 0 (0.00) | |
| Infusion product, n (%) | ||||
| Yescarta | 25 | 15 (93.75) | 10 (100.00) | 1 |
| Tecartus | 1 | 1 (6.25) | 0 (0) | |
| Primary refractory, n (%) | ||||
| No | 15 | 11 (73.33) | 4 (40.00) | .12 |
| Yes | 10 | 4(26.67) | 6 (60.00) | |
| MYC+FISH, n (%) | ||||
| No | 19 | 13 (86.67) | 6 (60.00) | .18 |
| Yes | 6 | 2 (13.33) | 4 (40.00) | |
| Double-hit FISH, n (%) | ||||
| No | 20 | 14 (93.33) | 6 (60.00) | .07 |
| Yes | 5 | 1 (6.67) | 4 (40.00) | |
| IPI at infusion (median) | 2 | 2 | 2 | 1 |
| IPI at infusion of ≥3, n (%) | ||||
| No | 19 | 13 (81.25) | 6 (60.00) | .37 |
| Yes | 7 | 3 (18.75) | 4 (40.00) | |
| Ann Arbor stage, n (%) | ||||
| I/II | 8 | 7 (33.75) | 1 (10.00) | .20 |
| III/IV | 18 | 9 (56.25) | 9 (90.00) | |
| Second-line or third-line or more CAR-T therapy, n (%) | ||||
| Second-line | 3 | 1 (6.25) | 2 (20.00) | .54 |
| Third-line or more | 23 | 15 (93.75) | 8 (80.00) | |
| Bridging therapy chemotherapy, n (%) | ||||
| No | 13 | 8 (50.00) | 5 (50.00) | 1 |
| Yes | 13 | 8 (50.00) | 5 (50.00) | |
| Bridging therapy, n (%) | ||||
| RT only | 1 | 0 (0) | 1 (16.67) | .43 |
| Systemic only | 13 | 8 (100.00) | 5 (83.33) | |
| Dexamethasone prophylaxis, n (%) | ||||
| No | 12 | 7 (43.75) | 5 (50.00) | 1 |
| Yes | 14 | 9 (56.25) | 5 (50.00) | |
| Characteristics | ||||
| Largest tumor diameter | ||||
| Mean, cm (range) | 5.77 (1.0-20.0) | 4.13 (1.1-10.0) | 8.41 (1.0-20.0) | .05 |
| Bulky, >5 cm, n (%) | ||||
| Yes | 10 | 4 (25.00) | 6 (60.00) | .11 |
| No | 16 | 12 (75.00) | 4 (40.00) | |
| Bulky, >7 cm, n (%) | ||||
| Yes | 7 | 2 (12.50) | 5 (50.00) | .07 |
| No | 19 | 14 (87.5) | 5 (50.00) | |
| Bulky, >10 cm, n (%) | ||||
| Yes | 6 | 2 (12.5) | 4 (40.00) | .16 |
| No | 20 | 14 (87.5) | 6 (60.00) | |
| SUVmax(mean ± SD) | 18.65 ± 10.94 | 14.97 ± 8.34 | 23.90 ± 12.64 | .10 |
| Disease response on preinfusion imaging, n (%) | ||||
| PD | 13 | 9 (56.25) | 4 (40.00) | .83 |
| Partial response | 8 | 4 (25.00) | 4 (40.00) | |
| Stable disease | 1 | 1 (6.25) | 0 (0.00) | |
| Stable disease/mixed | 2 | 1 (6.25) | 1 (10.00) | |
| N/A | 2 | 1 (6.25) | 1 (10.00) | |
| Circulating disease prior, n (%) | ||||
| Yes | 3 | 2 (13.33) | 1 (11.11) | 1 |
| No | 21 | 13 (86.67) | 8 (88.89) | |
| Extranodal disease, number of sites, n (%) | ||||
| 0 | 11 | 8 (50.00) | 3 (30.00) | .64 |
| 1 | 11 | 6 (37.50) | 5 (50.00) | |
| 2 | 3 | 2 (12.50) | 1 (10.00) | |
| 3 | 1 | 0 (0.00) | 1 (10.00) | |
| LDH at cell infusion, (mean ± STD), U/L | 288 ± 487 | 189 ± 32 | 445 ± 78 | .20 |
| LDH >190 U/L (ULN), n (%) | ||||
| No | 11 | 7 (43.75) | 4 (40.00) | 1 |
| Yes | 15 | 9 (56.25) | 6 (60.00) | |
| Ferritin at cell infusion, (mean ± SD), ng/mL | 456 ± 394 | 314 ± 202 | 684 ± 519 | .02 |
| Ferritin of >WNL, n (%) | ||||
| No | 16 | 13 (81.25) | 3 (30.00) | .02 |
| Yes | 10 | 3 (18.75) | 7 (70.00) | |
| CRP at cell infusion, (mean ± SD), mg/L | 30 ± 44 | 19 ± 27 | 48 ± 60 | .10 |
| CRP of >WNL, n (%) | ||||
| Yes | 10 | 3 (18.75) | 7 (70.00) | .02 |
| No | 16 | 13 (81.25) | 3 (30.00) |
DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; FL, follicular lymphoma; HGBCL, high grade B-cell lymphoma; IPI, International Prognostic Index; MCL, mantle cell lymphoma; N/A, not applicable; RT, radiation therapy; PMBCL, primary mediastinal B-cell lymphoma; SD, standard deviation; SUV, standard update value; ULN, upper limit of normal (based on institutional parameters); WLN, within normal limits.
P value ≤.05 considered as significant.